-
Most Muscle Pain on Statins Not a Drug Effect: SAMSON in Print
16 Sep 2021 16:37 GMT
… behind the randomized SAMSON trial, now fully published.
… Hopkins University School of Medicine, Baltimore.
Statin intolerance, he continues, … and the Imperial Clinical Trials Unit. Howard is … Kowa, Merck, Resverlogix, and Theravance; and serving on a …
-
The Daily Biotech Pulse: Leap, Phio, Silverback Among Early Movers On Oncology Conference Presentations, Aerie Slumps On Mixed Data, Axsome Commences Phase 3 Sleep Disorder Study
16 Sep 2021 11:52 GMT
… plc (NASDAQ: ACHL)
Acutus Medical, Inc. (NASDAQ: AFIB)
… Pharmaceuticals, Inc. (NASDAQ: SPPI)
Spruce Biosciences, Inc. (NASDAQ: SPRB)
Theravance … ophthalmic solution for the treatment of patients with … Ahead In Biotech (Sept. 12-18): Calliditas FDA Decision, …
-
Theravance Plunges as Potential Drug Fails, Forces 75% Cut in Headcount
15 Sep 2021 14:49 GMT
By Dhirendra Tripathi
Investing.com – Theravance Biopharma stock (NASDAQ:TBPH) … experimental hypotension drug ampreloxetine disappointed in a late-stage trial.
The stage … and commercialize respiratory therapeutics. Theravance expects to become cash flow …
-
Theravance Biopharma, Inc. Announces Top-line Results from a Phase 3 Study of Ampreloxetine in Patients with Symptomatic Neurogenic Orthostatic Hypotension
15 Sep 2021 14:03 GMT
… (NCT04095793); clinical trial sites will be notified … treatment of symptomatic neurogenic orthostatic hypotension (nOH).
About Theravance Biopharma
Theravance … medicines to treat respiratory disease, including FDA- … of our clinical trials or conclusions drawn …
-
Theravance Biopharma, Inc. Announces Strategic Actions to Focus on Respiratory Disease Portfolio
15 Sep 2021 14:03 GMT
… of respiratory medicines. Its core … FDA-approved YUPELRI® (revefenacin) inhalation solution indicated for the maintenance treatment … future clinical trials based … vaccine availability, distribution, acceptance and effectiveness. Other risks affecting Theravance …
-
Why Are Theravance Bio Shares Plummeting Premarket Today?
15 Sep 2021 12:55 GMT
Theravance Biopharma Inc (NASDAQ: TBPH) … in 2H of 2022.
Theravance will halt the development of … now on, Theravance will focus on COPD and asthma medicines, including Yupelri … million.
The restructuring came after Theravance announced topline data from the …
-
Theravance Biopharma To Cut 75% Jobs, Board Size; To Focus On Respiratory Disease Portfolio
15 Sep 2021 12:16 GMT
… and commercialization of organ-selective medicines, Wednesday announced strategic actions … study of ampreloxetine for the treatment of symptomatic neurogenic orthostatic … By implementing these strategic actions, Theravance expects to become sustainably cash …
-
The Daily Biotech Pulse: Lilly, Regeneron Ink COVID-19 Drug Deal With US, Regulatory Setback For Calliditas, Theravance To Cut 75% Jobs, 4 IPOs
15 Sep 2021 11:54 GMT
… Pharmaceuticals Inc. (NASDAQ: ACAD)
Acutus Medical, Inc. (NASDAQ: AFIB)
Avanos Medical … Treatments to U.S. Government
Regeneron Pharmaceuticals … Biotech: Calliditas FDA Decision, Adcom Review For Pfizer/BioNTech COVID-19 Vaccine …
Theravance Biopharma …
-
Theravance Biopharma shares slide 34% premarket on news to cut 75% of workforce in strategic overhaul
15 Sep 2021 10:41 GMT
Theravance Biopharma Inc. shares
TBPH,
-6. … it announced that a trial of a treatment of ulcerative colitis missed … sales of trelegy, a respiratory medicine developed with Glaxo, to peak … the SPDR S&P Biotech ETF
XBI,
-1.59%
has …
-
Theravance Biopharma: Ampreloxetine Phase 3 Study In NOH Patients Fails To Meet Primary Goal
15 Sep 2021 10:27 GMT
… medicines, Wednesday said its Phase 3 study of ampreloxetine for the treatment … activity on Nasdaq, Theravance Biopharma shares were losing … related to the study drug. No deaths were … Winningham, Chief Executive Officer, Theravance Biopharma, said, "These …
About
© 1995-2021